On October 18, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration (Press release, Phio Pharmaceuticals, OCT 18, 2021, View Source [SID1234591448]). These data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting, being held in Washington, D.C. on November 10-14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details are as follows:

Title:

Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model

Abstract Number:

869

Author:

Benjamin Cuiffo, et al.

Time and Date:

7:00 am – 8:30 pm ET on 11/12/2021

Location:

Poster Hall – Hall E

Poster presentations will be accessible in person and virtually. Posters will released on the SITC (Free SITC Whitepaper) website at 7:00 am ET on November 12, 2021 and will also be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).